Welche Patienten aus der Routinebetreuung verwenden das neue Insulin-AnalogonGlargin U300 im Vergleich zu Patientenmit

[1]  J. Rosenbauer,et al.  Glycated hemoglobin A1c as a risk factor for severe hypoglycemia in pediatric type 1 diabetes , 2017, Pediatric diabetes.

[2]  P. Bramlage,et al.  Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin , 2016, Acta Diabetologica.

[3]  C. Stettler,et al.  Variability of Basal Rate Profiles in Insulin Pump Therapy and Association with Complications in Type 1 Diabetes Mellitus , 2016, PloS one.

[4]  G. Dailey,et al.  A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine , 2015, Diabetes, obesity & metabolism.

[5]  M. Schütt,et al.  Gender-specific Effects of Treatment with Lifestyle, Metformin or Sulfonylurea on Glycemic Control and Body Weight: A German Multicenter Analysis on 9 108 Patients. , 2015, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[6]  R. Bergenstal,et al.  New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4) , 2015, Diabetes Care.

[7]  R. Roussel,et al.  Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes , 2015, Diabetes, obesity & metabolism.

[8]  R. Bergenstal,et al.  New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3) , 2015, Diabetes, obesity and metabolism.

[9]  U. Schwabe,et al.  Arzneiverordnungs-Report 2015 , 2015 .

[10]  M. Małecki,et al.  Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus , 2015, Acta Diabetologica.

[11]  Joan Minguet,et al.  U300, a novel long-acting insulin formulation , 2014, Expert opinion on biological therapy.

[12]  R. Bergenstal,et al.  New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2) , 2014, Diabetes Care.

[13]  S. Bain,et al.  Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials , 2014, Diabetes Therapy.

[14]  P. Home,et al.  New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1) , 2014, Diabetes Care.

[15]  M. Schütt,et al.  Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV‐wiss database , 2014, Diabetes/metabolism research and reviews.

[16]  Jennifer Y. Liu,et al.  Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. , 2014, JAMA internal medicine.

[17]  J. McGill,et al.  Impact of sex on the heart's metabolic and functional responses to diabetic therapies. , 2013, American journal of physiology. Heart and circulatory physiology.

[18]  P. Bramlage,et al.  DIabetes Versorgungs-Evaluation (DIVE) – eine nationale Initiative zur Qualitätssicherung in der diabetologischen Versorgung , 2013, Deutsche Medizinische Wochenschrift.

[19]  W. Rathmann,et al.  DIabetes Versorgungs-Evaluation (DIVE) – eine nationale Initiative zur Qualitätssicherung in der diabetologischen Versorgung , 2013, Deutsche Medizinische Wochenschrift.

[20]  D. Owens.  Insulin preparations with prolonged effect. , 2011, Diabetes technology & therapeutics.

[21]  R. Holl,et al.  Trends in der Insulinpumpentherapie bei Kindern, Jugendlichen und jungen Erwachsenen mit Typ-1-Diabetes von 1995-2006: Daten der DPV-Initiative , 2007 .

[22]  Mark G. Kosowski,et al.  Gender-specific care of the patient with diabetes: review and recommendations. , 2006, Gender medicine.

[23]  Nicholas Moore,et al.  Differences between clinical trials and postmarketing use. , 2003, British journal of clinical pharmacology.

[24]  Cunegundo M Vergara,et al.  Insulin glargine: a systematic review of a long-acting insulin analogue. , 2003, Clinical therapeutics.